Ulrich Storz
Michalski Hüttermann & Partner, Germany
Title: How AbbVie tries to fend off world’s blockbuster No 1 from generic competition
Biography
Biography: Ulrich Storz
Abstract
This presentation discusses the patent strategy underlying the world’s best selling drug, AbbVie’s Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. The presentation will discuss this portfolio in detail, and comment on its strengths and weaknesses.